Antiarrhythmic effects of phenytoin or dantrolene in patients with cardiomyopathy.

Phase 1

• Conditions: Heart failure with reduced ejection fraction (HFrEF); Arrhythmia; Cardiovascular - Other cardiovascular diseases; Cardiomyopathy

• Registration Number: ACTRN12619000730101
• Lead Sponsor: niversity of Newcastle

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-05-14
• Last Update Posted: 15 July 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 105

Inclusion Criteria

Patients:
• with cardiomyopathy, Ejection Fraction<35%
• with Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronisation Therapy (CRT)
• Aged 18 to 85

Exclusion Criteria

•Pregnant or breastfeeding females
•Childbearing age women (not on 2 contraceptive methods including non-oestrogen based OCP)
•Childbearing age women on oestrogen based OCP
•Inability to provide informed consent
•Patients with end stage kidney disease (eGFR<30) and patients on Dialysis
•Liver cirrhosis
•Patients with Aspartate transaminase (AST), and alanine transaminase (ALT) > 3 times upper limit of institutional normal value (ULN) on 2 measurements separated by at least 5 days
•Being prescribed the drug verapamil

Study & Design

• Study Type: Interventional
• Study Design: Not specified